Eli Lilly has struck a development deal with the research arm of Hutchison China-Meditech that is worth up to $29 million in milestones for each new drug candidate developed from its library of herbal remedies. The partnership marks another step forward for biotechnology R&D in China, as local companies strike up new deals with drug developers around the world. In addition to the milestones, Chi-Med is pocketing an undisclosed upfront fee along with payments to support the research, which will initially focus on oncology and inflammation. Some analysts say the deal should be a boon to China's drug development industry, which has been afflicted by a series of scandals.
- see this release
- read the article from The Telegraph
ALSO: What do you do with a booming antidepressant? Broaden its scope, of course. Eli Lilly has filed for FDA approval to sell Cymbalta as a fibromyalgia remedy. FiercePharma
Related Articles:
Merck KGaA inks deal with China's Chi-Med. Report
China pushes drug development as R&D soars. Report
China drug czar executed for corruption. Report
China to overhaul drug safety regulations. Report